In a liver transplant recipient, what preoperative testing for cytomegalovirus (CMV) IgG and IgM should be performed, and how should the results guide peri‑transplant management?

Preoperative CMV Testing in Liver Transplant Recipients

Both the liver transplant recipient and donor must undergo CMV IgG antibody testing preoperatively to establish serostatus and guide post-transplant prophylaxis strategy; CMV IgM testing is not recommended for pretransplant screening. 1

Testing Strategy

What to Test

• CMV IgG serology is mandatory for both donor and recipient before transplantation 1, 2, 3
• CMV IgM testing is NOT recommended for pretransplant screening in solid organ transplantation
  • IgM has significant variability across platforms with only fair-to-moderate agreement (κ = 0.34-0.58) 4
  • IgM can be negative or equivocal even in early primary infection (2.6% of cases) 5
  • IgM does not reliably distinguish active from latent infection in transplant candidates 6
  • The established technique for pretransplant screening is CMV IgG serology, not IgM 7

Method

• Use enzyme immunoassay (EIA) for CMV IgG detection 1
• IgG assays show robust performance across platforms with almost perfect agreement (κ = 0.91-0.95) and sensitivities of 96.9-99.1% 4

Risk Stratification Based on Results

The CMV serostatus determines post-transplant infection risk and management strategy:

Highest Risk: D+/R- (Donor positive, Recipient negative)

• Greatest risk factor for CMV infection post-transplantation 1, 3
• Primary infection from donor organ
• Requires most aggressive prevention strategy

High Risk: D+/R+ or D-/R+ (Recipient seropositive)

• Risk of reactivation or donor-related infection 1
• Requires surveillance and/or prophylaxis

Lowest Risk: D-/R- (Both seronegative)

• Minimal risk if CMV-safe blood products are used 8
• No prophylaxis or preemptive therapy recommended 8

Post-Transplant Management Implications

The pretransplant serology directly determines your prevention strategy:

• Universal antiviral prophylaxis is most widely used in high-risk patients (especially D+/R-) 7, 3, 8

  • Valganciclovir is the drug of choice 3, 8
  • No mandatory indication for universal prophylaxis in all SOT recipients 2

• Preemptive therapy is preferred in lower-risk patients 8

  • Requires CMV DNAemia monitoring by quantitative real-time PCR 2, 3
  • Monitoring should be performed for at least the first 4 months post-transplant 8

• CMV-specific cell-mediated immunity testing may be considered post-transplant to guide management duration, though its role is still being defined 2, 3

Critical Pitfalls to Avoid

• Do not rely on CMV IgM for pretransplant screening—it adds no value and may cause confusion due to poor specificity and sensitivity issues 6, 4, 5
• Do not skip donor testing—knowing only recipient status is insufficient for risk stratification 1
• Do not use the same prevention strategy for all serostatus combinations—D+/R- requires different management than D-/R- 8